Skip to main content
SpringerLink
Log in

Calcitonin gene-related peptide-targeting drugs: Raynaud's syndrome

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Gerard AO, et al. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database Journal of Headache and Pain : 10 May 2022. Available from: URL: http://doi.org/10.1186/s10194-022-01424-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Calcitonin gene-related peptide-targeting drugs: Raynaud's syndrome. Reactions Weekly 1906, 7 (2022). https://doi.org/10.1007/s40278-022-14897-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-14897-2

Search

Navigation